{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:45:07Z","timestamp":1790185507893,"version":"4.1.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2730,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN\/TPM ER) treatment on progression to type 2 diabetes and\/or cardiometabolic disease in subjects with prediabetes and\/or metabolic syndrome (MetS) at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight\/obese subjects (BMI \u226527 to \u226445 kg\/m2) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg\/TPM ER 46 mg (7.5\/46), or PHEN 15 mg\/TPM ER 92 mg (15\/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At baseline, 475 subjects met the criteria for prediabetes and\/or MetS. After 108 weeks, subjects with prediabetes and\/or MetS in the placebo, 7.5\/46, and 15\/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P &amp;lt; 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5\/46 and 15\/92, respectively (ITT, P &amp;lt; 0.05), versus placebo. The ability of PHEN\/TPM ER to prevent diabetes was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN\/TPM ER was well tolerated by this subgroup over 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>PHEN\/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight\/obese patients with prediabetes and\/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc13-1518","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T00:52:51Z","timestamp":1381279971000},"page":"912-921","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":193,"title":["Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release"],"prefix":"10.2337","volume":"37","author":[{"given":"W. Timothy","family":"Garvey","sequence":"first","affiliation":[{"name":"Department of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna H.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pennington Biomedical Research Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Henry","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine and the San Diego VA Medical Center, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.V.","family":"Bohannon","sequence":"additional","affiliation":[{"name":"Monteagle Medical Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[{"name":"Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwiers","sequence":"additional","affiliation":[{"name":"Medpace, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Troupin","sequence":"additional","affiliation":[{"name":"VIVUS, Inc., Mountain View, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley W.","family":"Day","sequence":"additional","affiliation":[{"name":"VIVUS, Inc., Mountain View, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,3,8]]},"reference":[{"key":"2022031221551929000_B1","unstructured":"Centers for Disease Control and Prevention. Diabetes public health resource: 2007 national diabetes fact sheet. Atlanta, GA, Centers for Disease Control and Prevention, 2007"},{"key":"2022031221551929000_B2","unstructured":"The facts about diabetes: a leading cause of death in the U.S. Bethesda, MD, National Diabetes Education Program. Available from http:\/\/ndep.nih.gov\/diabetes-facts\/index.aspx. Accessed 14 May 2012"},{"key":"2022031221551929000_B3","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221551929000_B4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","article-title":"Impaired fasting glucose and impaired glucose tolerance: implications for care","volume":"30","author":"Nathan","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031221551929000_B5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2022031221551929000_B6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1463-1326.2008.00925.x","article-title":"Risk factor assessment for new onset diabetes: literature review","volume":"11","author":"Bakris","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031221551929000_B7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"2022031221551929000_B8","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"2022031221551929000_B9","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.2337\/diacare.26.11.3153","article-title":"The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study","volume":"26","author":"Lorenzo","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031221551929000_B10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"2022031221551929000_B11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","article-title":"Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031221551929000_B12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031221551929000_B13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031221551929000_B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11936-005-0007-1","article-title":"Current treatment options for the metabolic syndrome","volume":"7","author":"Deedwania","year":"2005","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2022031221551929000_B15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11892-010-0163-x","article-title":"Update on the prevention of type 2 diabetes","volume":"11","author":"Karam","year":"2011","journal-title":"Curr Diab Rep"},{"key":"2022031221551929000_B16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0026-0495(90)90299-R","article-title":"UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group","volume":"39","author":"UK Prospective Diabetes Study 7","year":"1990","journal-title":"Metabolism"},{"key":"2022031221551929000_B17","first-page":"CD005270","article-title":"Long-term non-pharmacological weight loss interventions for adults with prediabetes","volume":"18","author":"Norris","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031221551929000_B18","unstructured":"National Heart, Lung, and Blood Institute. Identification, evaluation, and treatment of overweight and obesity in adults, 2000 [Internet]. Available from http:\/\/www.nhlbi.nih.gov\/guidelines\/obesity\/prctgd_c.pdf. Accessed 8 February 2013"},{"key":"2022031221551929000_B19","unstructured":"Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes: a position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention: International Diabetes Federation Consensus Panel, 2011 [Internet]. Available from http:\/\/www.bakeridi.edu.au\/Assets\/Files\/IDF-Position-Statement-Bariatric-Surgery.pdf. Accessed 8 February 2013"},{"key":"2022031221551929000_B20","first-page":"CD003641","article-title":"Surgery for obesity","volume":"15","author":"Colquitt","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031221551929000_B21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3810\/pgm.2011.01.2243","article-title":"The pharmacological treatment and management of obesity","volume":"123","author":"Hussain","year":"2011","journal-title":"Postgrad Med"},{"key":"2022031221551929000_B22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa1112082","article-title":"Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects","volume":"367","author":"Carlsson","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031221551929000_B23","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/oby.2010.27","article-title":"Maladaptive eating patterns, quality of life, and weight outcomes following gastric bypass: results of an Internet survey","volume":"18","author":"Kofman","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"2022031221551929000_B24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022031221551929000_B25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"2022031221551929000_B26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2022031221551929000_B27","volume-title":"The LEARN Program for Weight Management","author":"Brownell","year":"2000"},{"key":"2022031221551929000_B28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/met.2004.2.82","article-title":"The metabolic syndrome and inflammation","volume":"2","author":"Sutherland","year":"2004","journal-title":"Metab Syndr Relat Disord"},{"key":"2022031221551929000_B29","doi-asserted-by":"crossref","first-page":"e6624","DOI":"10.1371\/journal.pone.0006624","article-title":"Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods","volume":"4","author":"Elobeid","year":"2009","journal-title":"PLoS ONE"},{"key":"2022031221551929000_B30","volume-title":"Multiple Imputation for Nonresponse in Surveys. Wiley Series in Probability and Mathematical Statistics","author":"Rubin","year":"1987"},{"key":"2022031221551929000_B31","volume-title":"Analysis of Incomplete Multivariate Data (Monographs on Statistics and Applied Probability 72)","author":"Schafer","year":"1997"},{"key":"2022031221551929000_B32","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/dc06-0560","article-title":"Effect of weight loss with lifestyle intervention on risk of diabetes","volume":"29","author":"Hamman","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031221551929000_B33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/diabetes.54.1.158","article-title":"Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study","volume":"54","author":"Laaksonen","year":"2005","journal-title":"Diabetes"},{"key":"2022031221551929000_B34","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"2022031221551929000_B35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study","volume":"368","author":"Lindstr\u00f6m","year":"2006","journal-title":"Lancet"},{"key":"2022031221551929000_B36","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","article-title":"The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study","volume":"371","author":"Li","year":"2008","journal-title":"Lancet"},{"key":"2022031221551929000_B37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MOL.0b013e32814a645f","article-title":"Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease","volume":"18","author":"Lara-Castro","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"2022031221551929000_B38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.mcna.2011.06.002","article-title":"Insulin resistance: the link between obesity and cardiovascular disease","volume":"95","author":"Reaven","year":"2011","journal-title":"Med Clin North Am"},{"key":"2022031221551929000_B39","unstructured":"Wing R, Gillis B. The Diabetes Prevention Program\u2019s Lifestyle Change Program. Pittsburgh, PA, University of Pittsburgh, 1996. Available from http:\/\/www.bsc.gwu.edu\/dpp\/lifestyle\/DPP_duringcore.pdf. Accessed 8 February 2013"},{"key":"2022031221551929000_B40"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/4\/912\/620235\/912.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/4\/912\/620235\/912.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:08:05Z","timestamp":1647112085000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/4\/912\/32276\/Prevention-of-Type-2-Diabetes-in-Subjects-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,8]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,3,8]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-1518","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,8]]}}}